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Abstract
Aims Inpatients with heart failure and renal impairment have poor outcomes and variable quality of care. We investigate
treatment practice and outcomes in an unselected real-world cohort using historical creatinine measurements.
Methods and results Admissions between 1/4/2013 and 30/4/2015 diagnosed at discharge with heart failure were
retrospectively analysed. Stages of chronic kidney disease (CKD) and acute kidney injury (AKI) were calculated from creatinine
at discharge and 3–12 months before admission. We identiﬁed 1056 admissions of 851 patients (mean age 76 years, 56%
Caucasian, 36% with diabetes mellitus, 54% with ischaemic heart disease, and 57% with valvular heart disease). CKD was
common; 36%—Stage 3a/b, 11%—Stage 4/5; patients were older, more often diabetic, with higher potassium, lower
haemoglobin, and more oedema but similar prevalence of left ventricular systolic dysfunction (LVSD) compared patients with
Stages 0–2. AKI was present in 17.0% (10.4%—Stage 1, 3.7%—Stage 2, and 2.9%—Stage 3); these had higher potassium and
lower haemoglobin than patients with no AKI. Length of stay was longer in Stage 4/5 CKD [11 days; P = 0.008] and AKI [13 days;
P = 0.006]. Mortality was higher with Stage 4/5 CKD (13.8% compared with 7.7% for Stages 0–2 CKD (P = 0.036)] and increased
with AKI (5%—no AKI, 20.9%—Stage 1, 35.9%—Stage 2, and 48.4%—Stage 3; P< 0.001). Adjusted for age, diabetes, and LVSD,
both AKI and Stage 4/5 CKD were independent predictors of in-hospital mortality. In survivors with LVSD, the discharge
prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers decreased with progressive CKD,
[84%—no-mild, 59%—moderate, and 36%—severe CKD; P < 0.001]; this was not purely explained by hyperkalaemia.
Conclusions Inpatients with heart failure and renal impairment, acute and chronic, failed to receive recommended therapy
and had poor outcomes.
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Introduction
Heart failure is a signiﬁcant and growing public health
problem. In England, over the year 2014–15, there were
764 977 admissions coded with heart failure as a diagnosis,
with 70 890 of them in the ﬁrst diagnostic position.1 Whilst
progress has been made with prognosis-modifying therapies
in heart failure with left ventricular systolic dysfunction
(LVSD), cases where ejection fraction is apparently preserved
and where patients have multiple comorbidities remain a
management challenge. The National Heart Failure Audit for
England and Wales revealed that patients had poor but still
highly variable outcomes; patients aged <75 years and those
managed on cardiology wards had a lower mortality of
approximately 5%, compared with over 15% in other groups.2
Renal impairment on admission in patients admitted with
heart failure is common, present in approximately half, and
associated with high mortality.3–5 Similarly, worsening renal
failure during acute admissions with heart failure is associated
with increased length of stay, high cost, and up to eight-fold
higher mortality.6,7 However, the cause of poor outcome
associated with renal impairment in heart failure patients is
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unclear. The neurohumoral signalling pathways and
bidirectional haemodynamic interplay between the heart,
the kidney, and therapy for heart failure in the healthy and
impaired functional state are complex, and it has been
observed that differing degrees, reversibility, and underlying
causes of renal impairment have different prognostic
implications.8,9 Previous studies have had a heterogeneous
deﬁnition for renal impairment, with few using a historical
(pre-admission) creatinine to assess chronicity of renal
impairment.
Trials of treatments in heart failure often exclude patients
with chronic kidney disease (CKD), leaving the evidence-base
in this area relatively poor.10 Consequently, national and
international guidelines and recommendations are required
to extrapolate the beneﬁcial impact of disease-modifying
therapies and leave a degree of the decision-making in the
hands of the clinicians.11–14 It has been demonstrated that
adherence to recommendations regarding prescription of
disease-modifying therapies is variable and is impacted by
renal function in trial settings.2,15,16 It is not well known what
impact renal impairment has on prescribing in current clinical
practice, particularly when such patients are managed by
non-cardiologists and non-nephrologists. In this study, we
examine outcomes and prescribing practices in heart failure
patients with and without renal impairment, using historic
baseline creatinine measurements, in a hospital-wide cohort
of patients from a multi-ethnic, inner-city community.
Methods
Patient identiﬁcation and data collection
We undertook detailed analysis of data submitted from one
hospital trust in England to the National Heart Failure Audit
from April 2013 to April 2015 inclusive. These were
retrospectively collected data on unscheduled admissions to
an inner city UK teaching hospital coded on discharge with a
primary diagnosis of heart failure or its accepted equivalents.
Data were collected in accordance with the National Heart
Failure Audit2,17 to which the trust submitted 98% of the
Hospital Episodes Statistics (HES) registered primary heart
failure diagnosis 2013–14.18 LVSD was deﬁned by left
ventricular ejection fraction of <40%. Loop diuretic doses
were converted into furosemide equivalents, for example
1 mg of Bumetinide is equivalent to 40 mg of Furosemide.
Renal function data
Creatinine levels on discharge had been recorded routinely
using the audit tool.18 Additionally, a prior baseline creatinine
level was obtained from electronic patient notes; the latest
reading that was more than 3 months but less than 12 months
prior to admission. Estimated glomerular ﬁltration rate
(eGFR) was calculated using the Modiﬁcation of Diet in Renal
disease (MDRD) formula19 and converted to CKD stages using
the Kidney Disease Improving Global Outcomes criteria.20
Severity of acute kidney injury (AKI) was determined by
degree of acute change from baseline creatinine to discharge
creatinine using the Kidney Disease Improving Global
Outcomes criteria.21
Data clean-up and imputation of missing values
Patients discharged outside the speciﬁed time criteria and true
duplicate entries were removed (10 admissions total). Special
attention was paid to ensure no duplication of in-hospital
death was recorded. Where a baseline creatinine was
unavailable, there was assumed to be no CKD (Stage 0). In
these cases, an AKI was assumed in the presence of a discharge
creatinine above the normal range with the stage of AKI
estimated based on the degree of elevation. Missing data from
other variables were not imputed; if data were transformed to
a dichotomous category, missing data points were coded as not
being present. Where statistical analysis is made on a subset of
the data, this is indicated in the relevant results section.
Statistical analysis
Mean, standard deviation (SD), and interquartile range (IQR)
were determined for quantitative variables, frequency, and
percentages for categorical variables. The inferential
statistical analyses performed were independent samples
t-tests for quantitative variables comparing two groups,
one-way ANOVA tests comparing more than two groups
and Pearson χ2 tests for categorical variables. Two-sided
P-values were calculated with a value of <0.05 considered
statistically signiﬁcant. Binomial logistic regression was
performed for in-hospital mortality.
Results
Demographics and general observations
During the period April 2013–April 2015 inclusive, there were
1056 episodes where patients were discharged with a
primary diagnosis of heart failure. These episodes relate to
851 individual patients, revealing a cohort of patients with
repeated admissions during the investigated time frame.
Baseline data for these individual patients are as follows.
There were marginally more men (55.8%) than women,
overall the population was elderly (mean age 75.9 years, SD
13.4), and multi-ethnic, with 56.4% White and the remaining
43.6% of non-Whites [a spread of Asian (16.9%), Black
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(12.2%), and other (14.5%)]. Over a third of patients had
diabetes mellitus (36.2%), and over half of patients had
ischaemic heart disease (54.5%), valvular heart disease
(57.3%), and hypertension (63.6%). Considering the main
place of care for the total number of admissions, the large
majority of patients were cared for on General Medical wards
(61.7%) with 31.7% on specialist cardiology wards.
Chronic kidney disease
Baseline creatinine readings were available in 954 admissions
(90.3%). Those with no recorded baseline were assumed to
have CKD Stage 0 or 1 (eGFR > 90 mL/min/1.73m2).
Prevalence and mortality ﬁgures for the stages of CKD are
shown in Table 1. Approximately 75.28% of admissions had
a baseline eGFR of <90 mL/min/1.73 m2, and 47.35% had
an eGFR of<60 mL/min/1.73m2. Approximately 10.98% of
admissions had an eGFR<30 mL/min/1.73m2.
Admissions were grouped into three broader categories of
CKD; no-mild CKD (Stages 0, 1, and 2), moderate (Stages 3a
and 3b), and severe CKD (Stages 4 and 5). Characteristics
are detailed in Table 2. The no-mild CKD patients were the
youngest (73.84 years) compared with moderate CKD
(79.01 years) and severe CKD (78.27 years). Haemoglobin
levels decreased as CKD severity advanced (no-mild CKD
12.3 g/L, moderate CKD 11.4 g/L, and severe CKD 10.3 g/L),
whilst mean serum potassium concentration [K+] increased
as CKD stage advanced (no-mild CKD 4.2 mmol/L, moderate
4.4 mmol/L, and severe 4.6 mmol/L). The highest proportion
of patients with moderate–severe oedema was in the
moderate CKD group (61.8%). There was no difference
between the three groups regarding worse symptoms of
breathlessness (New York Heart Association grading III–IV),
or percentage with LVSD. There were fewer patients with
diabetes mellitus in the no-mild CKD group (27.1%) compared
with the moderate (49.2%) and severe groups (58.6%). Blood
pressure parameters were poorly recorded with almost 50%
of cases missing, but there was a suggested trend towards
higher blood pressure as severity of CKD worsened. There
was no statistically signiﬁcant difference between the
proportions of patients managed on a cardiology ward.
Discharge medications (analysed in survivors to
discharge)
Medications that were prescribed on discharge were analysed
only in those patients that survived to discharge. The group
of medications speciﬁcally recommended for patients with
LVSD—angiotensin-converting enzyme (ACE)-Inhibitors,
angiotensin receptor blockers (ARB), beta-blockers, and
mineralocorticoid receptor antagonists (MRA)—were only
analysed in those patients known to have LVSD. Diuretic dose
(converted to Furosemide dose equivalents) was analysed in
all survivors regardless of LVSD. There were a total of 555
admissions comprising survivors to discharge with LVSD, 288
had no-mild CKD, 209 had moderate, and 58 had severe CKD.
The percentage of patients prescribed on discharge an
ACE/ARB, MRA, or ‘triple therapy’ (ACE/ARB, MRA, and beta-
blocker prescribed simultaneously) fell as the degree of CKD
worsened, but there was no statistically signiﬁcant difference
between the CKD groups when comparing beta-blocker
prescription or digoxin prescription (Figure 1). Diuretic dose was
signiﬁcantly lower in the no-mild CKD group compared with the
moderate group and severe group, but the difference between
the moderate and severe groups was non-signiﬁcant (Table 2).
The inﬂuence of hyperkalaemia on ACE or ARB and
MRA prescription
The number of cases of survivors to discharge with LVSD
being prescribed ACE/ARB or MRA was analysed according
to serum potassium concentration [K+], using different
thresholds of [K+] (Table 3). As the threshold potassium was
increased, the percentage of cases not prescribed ACE/ARB
increased in both patients with eGFR > 60 mL/min/1.73m2
and eGFR < 60 mL/min/1.73m2 (Figure 2). With MRA
prescription, the percentages of cases not prescribed MRA
on discharge were more static with lower thresholds of
potassium but an increasing percentage were not prescribed
MRAs when [K+]> 5.0 mmol/L. The CKD stage was associated
with a statistically signiﬁcant difference in the percentages of
cases prescribed ACE/ARB or MRA on discharge only up to a
threshold [K+] > 5.0 mmol/L (Figure 3). There was a
statistically signiﬁcant difference between the
eGFR > 60 mL/min/1.73m2 and eGFR < 60 mL/min/1.73m2
groups in the percentage of patients with no ACE/ARB or
MRA prescription when [K+] < 4.0, >4.0, and >4.5 mmol/L,
with no statistically signiﬁcant difference found between
the two groups at higher thresholds of [K+].
There was no signiﬁcant difference in the mean [K+] between
the group on ACE/ARB and not; mean [K+] in the
Table 1 Frequency and in-hospital mortality by chronic kidney
disease stage (all admissions)
CKD
stage
Number (% of total
admissions)
Death in hospital
(%)
Age in years
(mean and SD)*
0 or 1 261 (24.72) 20/261 (7.66) 70.69 (15.57)
2 295 (27.94) 23/295 (7.80) 76.63 (12.08)
3a 193 (18.28) 21/193 (10.88) 76.79 (11.03)
3b 191 (18.09) 16/191 (8.38) 79.66 (9.20)
4 94 (8.90) 14/94 (14.89) 79.55 (10.87)
5 22 (2.08) 2/22 (9.09) 72.77 (16.12)
CKD, chronic kidney disease; SD, standard deviation.
*Reached statistical signiﬁcance in one-way ANOVA test using
Games–Howell post hoc test between Stages 2 and 3b
(P = <0.001) and between Stages 0/1 and 3b (P = 0001).
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eGFR < 60 mL/min/1.73m2 group prescribed ACE/ARB was
4.44 mmol/L (SD 0.64) and in the eGFR < 60 mL/min/1.73m2
group not prescribed ACE/ARBwas 4.37mmol/L (SD 0.52) where
P = 0.353. In the group where eGFR> 60 mL/min/1.73m2, those
prescribed ACE/ARB had a mean [K+] of 4.19 mmol/L (SD 0.45)
compared with 4.38 mmol/L (SD 0.62) in those with no
ACE/ARB was prescribed, where P = 0.050.
Acute kidney injury
Approximately 17.0% of admissions had an AKI (Table 4).
Severe AKI was not common overall (10.4% of total
admissions had Stage 1 AKI, 3.7% had Stage 2 AKI, and
2.9% Stage 3 AKI). The presence of any AKI stratiﬁed by
CKD grouping is shown in Table 2. More signiﬁcant AKI
Figure 1 Use of medications with different stages of chronic kidney disease in patients with left ventricular systolic dysfunction. ACE, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; MRA, mineralocorticoid receptor antagonist. No-mild
CKD, no CKD or CKD Stages 1–2; moderate CKD, CKD Stages 3a–3b; severe CKD, CKD Stages 4–5.
Table 3 Percentage of patients with estimated glomerular ﬁltration rate above and below 60 mL/min/1.73m2 not prescribed angiotensin-
converting enzyme inhibitor/angiotensin receptor blocker and mineralocorticoid receptor antagonist according to serum potassium
threshold cut-off
eGFR > 60 mL/min/1.73m2 eGFR < 60 mL/min/1.73m2
P value(Stage 0–2 CKD) (Stage 3–5 CKD)
[K+] < 4.0 mmol/L
Not on ACE/ARB 12/85 (14.1%) 28/61 (45.9%) P < 0.001
Not on MRA 39/85 (45.9%) 42/61 (68.9%) P = 0.006
[K+] > 4.0 mmol/L
Not on ACE/ARB 35/203 (17.2%) 93/204 (45.6%) P < 0.001
Not on MRA 85/203 (41.9%) 135/204 (66.2%) P < 0.001
[K+] > 4.5 mmol/L
Not on ACE/ARB 21/84 (25.0%) 60/121 (49.6%) P < 0.001
Not on MRA 40/84 (47.6%) 82/121 (67.8%) P = 0.004
[K+] > 5.0 mmol/L
Not on ACE/ARB 8/19 (42.1%) 27/51 (52.9%) P = 0.420
Not on MRA 10/19 (52.6%) 36/51 (70.6%) P = 0.159
[K+] > 5.5 mmol/L
Not on ACE/ARB 3/4 (75.0%) 8/10 (80.0%) P = 0.837
Not on MRA 4/4 (100.0%) 9/10 (90.0%) P = 0.512
[K+] > 6.0 mmol/L
Not on ACE/ARB 1/1 (100.0%) 1/1 (100.0%) N/A
Not on MRA 1/1 (100.0%) 1/1 (100.0%) N/A
ACE/ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; eGFR, estimated glomerular ﬁltration rate; [K+],
serum potassium concentration; MRA, mineralocorticoid receptor antagonist; N/A, not applicable.
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(Stages 2 and 3) was present in 46 (8.3%) of admissions
with no-mild CKD, 18 (4.7%) with moderate CKD, and 6
(5.2%) of admissions with severe CKD (P = 0.074). Those
with any AKI had a higher mean [K+] (4.62 mmol/L SD
0.84) compared with those without AKI (4.26 mmol/L,
SD 0.64; P < 0.001), and lower haemoglobin
concentration (11.5 g/L, SD 2.2) compared with those
without AKI (11.8 g/L, SD 2.0; P = 0.046). Those with
AKI tended to be older, but this did not reach statistical
signiﬁcance (77.6 years, SD 10.6 with AKI compared with
75.9 years, SD 13.3 without AKI; P = 0.066). There was
a trend towards a lower percentage prescription of
ACE/ARB on discharge (in survivors to discharge with
LVSD) where a patient suffered a signiﬁcant AKI (Stage
2 or 3, 52.2%) compared with no or Stage 1 AKI
(70.3%), but this did not reach statistical signiﬁcance
(P = 0.064). Similarly with MRA prescription on discharge,
46.1% with no or Stage 1 AKI had MRA prescription of
discharge, whereas 30.4% with Stage 2 or 3 AKI had
MRA on discharge (P = 0.141).
Figure 3 Lack of mineralocorticoid use with increasing serum potassium in patients with left ventricular systolic dysfunction. Showing percentage of
patients not on mineralocorticoid receptor antagonist with rising levels of serum potassium in patients above and below an estimated glomerular
ﬁltration rate (eGFR) of 60 mL/min/1.73m2. K, serum potassium in mmol/L.
Figure 2 Lack of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy with increasing serum potassium in patients with left
ventricular systolic dysfunction. Showing percentage of patients not on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker with
rising levels of serum potassium, separately in patients above and below estimated glomerular ﬁltration rate (eGFR) of 60 mL/min/1.73m2. K, serum
potassium in mmol/L.
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Mortality, length of stay, and readmissions with
renal impairment
The total number of recorded deaths during the same hospital
admission was 96 (9.1% of admissions). The death rate
increased as CKD stage advanced (Table 2). The presence of
an AKI was associated with a profound increase in mortality
correlating to the degree of severity of AKI (Table 4).
A logistic regression was performed to ascertain the
effects of age, diabetes, LVSD, AKI, and severe CKD
(eGFR < 30 mL/min/1.73m2) on the likelihood on in-hospital
death. AKI and CKD remained independent predictors of in-
hospital death (Table 5).
Patients with no-mild CKD had a tendency towards a
shorter median length of stay of 6 days compared with 8 days
for moderate and 11 days for severe (Table 2). Patients with
AKI had signiﬁcantly longer length of hospital stay; 12.68 days
(IQR 13) compared with 9.91 days (IQR 12) without AKI
P = 0.006.
The baseline CKD stage was analysed in the individual
patients (851) from their ﬁrst admission (Table 2). The
number of total admissions with heart failure for each
individual patient during the study time frame was analysed
according to this ﬁrst presenting CKD stage. There were more
readmissions in the more advanced CKD groups compared
with no-mild CKD (Table 2).
The use of ACE-I/ARB in admissions with LVSD was more
common than in admissions with no LVSD (70.66% vs.
54.23%; P < 0.001). Similarly, admissions with LVSD were
more likely to be on beta-blockers (84.27% vs. 64.52%;
P < 0.001) and MRA (46.23% vs. 14.59%; P < 0.001) at
discharge. Serum potassium was similar between admissions
with and without LVSD (4.35 ± 0.60 vs. 4.30 ± 0.66 mmol/L;
P = 0.0260). Inpatient mortality was also similar between
the two groups (10.26% vs. 10.64%; P = 0.850).
Discussion
This observational analysis of a large real-world cohort of
patients with heart failure using pre-admission creatinine
readings demonstrates adverse outcomes in the presence of
renal impairment, both acute and chronic, particularly
mortality. Both severe CKD and AKI were independent
predictors of mortality. The length of stay was longer in
severe CKD and AKI patients. Readmission rates were higher
in patients with moderate CKD. Detailed analysis of
medications on discharge highlights the lack of use of
evidenced-based therapy in LVSD and in a signiﬁcant
proportion of cases these therapies were not used despite
the levels of potassium being safe.
Some unexpected results merit discussion. To see higher
rates of AKI in no CKD is counter-intuitive. It is possible that
these are milder grades of AKI. It is increasingly recognized
that the relationship between acute renal impairment and
outcomes is more complex than ﬁrst thought. Prognosis does
not simply depend on a single time-point creatinine above
the normal range but has been shown to be complex than
this.7 Similarly, it has been suggested that not all episodes
of AKI confer the same poor outcomes on a population with
heart failure9; rising creatinine in response to
commencement of ACE/ARB has different prognostic
implications compared with sepsis-related AKI, but these
cannot be distinguished in this retrospective data analysis.
Furthermore, the apparently lower mortality in CKD Stage 5
is unanticipated. Low mortality in CKD Stage 5 may represent
a population of dialysis-dependent patients admitted for ﬂuid
removal and discharged, though the mortality is higher in the
long run.22 Those with CKD Stage 5 are also younger, and
many fewer numbers mean the statistical inﬂuence of
individual patients is much greater. The blood pressure
ﬁndings with progressive CKD are also unexpected. One
traditional explanation for renal impairment in heart failure
is hypoperfusion of the renal parenchyma due to low systolic
blood pressures. This study has shown the blood pressures
are greater in worse CKD, which could be related to the lower
proportion taking an ACE/ARB or may suggest that a more
complex pathogenic mechanism is at work.
Some important points must be made about the
limitations of these data, such as absence of data on blood
pressure at admission. In addition to the recognized inherent
Table 4 Incidence and in hospital mortality of stages of acute
kidney injury in all admissions
Stage of AKI Frequency (%) Mortality P < 0.001
No AKI 876 (83.0) 44/876 (5.0%)
1 110 (10.4) 23/110 (20.9%)
2 39 (3.7) 14/39 (35.9%)
3 31 (2.9) 15/31 (48.4%)
AKI, acute kidney injury.
Table 5 Binomial logistical regression for in-hospital mortality
Variable B S.E. Wald P value EXP(B) 95% CI for EXP (B)
Systolic dysfunction 0.105 0.249 0.178 0.673 0.900 0.553 1.466
Any AKI 2.029 0.242 70.244 <0.001 0.131 0.082 0.211
Diabetes mellitus 0.135 0.012 10.576 0.583 0.874 0.540 1.414
Severe CKD (eGFR < 30 mL/min/1.73m2) 0.677 0.331 4.173 0.041 0.508 0.265 0.973
Age 0.040 0.012 0.001 1.040 1.016 1.065
Constant 3.312 1.021 10.518 0.001 0.036
AKI, acute kidney injury; CI, conﬁdence interval; CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate.
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limitations in datasets collected retrospectively for audit
purposes and limited to a single hospital database, speciﬁc
factors must be considered relating to the collection of renal
function data. Our estimations of CKD and AKI are crude and
subject to bias generated by time-point collections. Firstly, by
interpreting creatinine results at discharge, we are likely to
have underestimated the incidence of AKI; few patients are
likely to have been discharged home with an evolving AKI
or at peak creatinine. Secondly, a single measurement of
baseline renal function captured purely using time-deﬁned
criteria may overestimate the severity of CKD and
subsequently underestimate AKI. A proportion of the patients
in this cohort have repeated admissions to hospital capture in
this audit alone, and the possibility remains of other
intercurrent illnesses; each could result in previous episodes
of AKI recorded as their assumed baseline renal function.
Mortality in AKI may well have been overestimated using a
discharge time-point creatinine. It is worth noting that
discharge creatinine readings are what is collected routinely
on a national level using the audit dataset.19
What is highly signiﬁcant is the poorer take-up in
prescription of some potentially disease-modifying medicines
(ACE/ARB and MRA) for LVSD in patients with increasing CKD.
Clearly, given that the evidence base for these medications in
this subgroup of patients is poorer and there is a real risk of
signiﬁcant side-effects, notably hyperkalaemia, prescribing
practices in individual cases may well deviate from best
practice guidelines. However, this study demonstrates that a
signiﬁcant proportion of patients with eGFR < 60 mL/min/
1.73m2 with a potassium level, at least on discharge, well
within the normal range were not prescribed an ACE/ARB
(45.9%) or MRA (65.6%). The possibility is raised that in cases
of moderate–severe CKD, potentially beneﬁcial medications
may be being inappropriately withheld. This analysis needs
repeating on a larger scale to ensure these ﬁndings are
representative of wider practice. In addition, further
qualitative work needs to be performed to assess the reasons
for non-prescription of recommended therapies, which may
include, as well as predictable clinical contra-indications,
non-documented ‘contextual factors’23 as well as physician
factors such as lack of expertise in non-specialists.16
Additionally, further randomized controlled trials are needed
that include patients with more advanced CKD to ascertain
the beneﬁt of potentially disease-modifying therapies,24 and
there is a potential role for the novel potassium binders in
those cases where hyperkalaemia is preventing their use.25
Meanwhile, consideration should be given to augmenting
national audit datasets with more details on renal function
to capture temporal variation. The routine inclusion of
nephrologists in the specialist heart failure multidisciplinary
team may allow a more nuanced assessment of the risks
and beneﬁts of different management strategies in this group
of patients that continue to represent a very real
management challenge.
Conclusions
In conclusion, this study in multi-ethnic, inner-city, heart
failure patients re-established association of chronic and
acute renal impairment with poor outcome and suboptimal
medical therapy, highlighting the need for multidisciplinary
approach and better evidence for treatment, to improve
morbidity and mortality.
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